103 completed. 103 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 103 | Completed 103 |
Follow Retinal Degeneration: new trials by email Literature Review of Retinal Degeneration trials Research Report on Retinal Degeneration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Patient Comfort Following Intravitreal Injections Using Iheezo Versus Standard Anesthesia Iheezo, Lidocaine pledget - Macular Degeneration, Diabetic Retinopathy | Phase 4 | Completed | Retina Consultants of Delmarva | 50 | 2026-05-20 | 2026-08-21 |
| Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema. brolucizumab - Diabetic Macular Edema | Phase 4 | Completed | Novartis Pharmaceuticals | 66 | 2024-12-11 | 2026-04-13 |
| Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment Aflibercept 8mg - Age-related Macular Degeneration (ARMD) | Phase 4 | Completed | Kim's Eye Hospital | 35 | 2024-10-21 | 2026-07-16 |
| Ocular Safety and Usability Study for FYB203 PFS FYB203 2 mg (0.05 mL of 40 mg/mL) - Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema | Phase 4 | Completed | Formycon AG | 30 | 2024-09-20 | 2024-11-27 |
| Ocular Safety and Usability Study for FYB201 PFS FYB201 0.5 mg (0.05 mL of 10 mg/mL) - Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema | Phase 4 | Completed | Formycon AG | 31 | 2024-06-11 | 2024-11-27 |
| Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp, Prolensa 0.07% Ophthalmic Solution - Corneal Edema, Corneal Defect | Phase 4 | Completed | Nicole Fram M.D. | 50 | 2023-06-01 | 2026-02-20 |
| Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery Bromfenac, Moxifloxacin 0.5% ophthalmic solution, Dexamethasone phosphate 0.1% - Cataract, Cystoid Macular Edema After Phacoemulsification | Phase 4 | Completed | Inas Abd | 87 | 2023-05-01 | 2025-05-06 |
| Manage Macular Cystoid Edema With Retinal Vein Obstruction Using Traditional Chinese Medicine and Ranibizumab Jueling Mingmu decoction, intravitreal injections of 0.5mg ranibizumab - Macular Cystoid Edema | Phase 4 | Completed | Dongyang People's Hospital | 111 | 2023-01-01 | 2025-08-22 |
| Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E Brolucizumab, Aflibercept - Age-Related Macular Degeneration | Phase 4 | Completed | The University of Hong Kong | 30 | 2022-07-25 | 2024-05-08 |
| Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD) Injection Brolucizumab - Neovascular Age-related Macular Degeneration (nAMD) | Phase 4 | Completed | Novartis Pharmaceuticals | 105 | 2022-03-09 | 2025-03-20 |
| Cool vs Room-temperature Artificial Tears Refresh Plus Preservative-free Lubricant Eye Drops - Diabetic Retinopathy With Macular Edema of Both Eyes (Diagnosis), Central Retinal Vein Occlusion With Macular Edema | Phase 4 | Completed | University of Iowa | 124 | 2022-03-01 | 2025-03-04 |
| Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab. Brolucizumab - Neovascular Age-related Macular Degeneration | Phase 4 | Completed | Novartis Pharmaceuticals | 122 | 2021-10-15 | 2025-05-16 |
| Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period Bromfenac Sodium 0.07%, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly, Propylene Glycol Preservative-free Artificial Tears - Vein Occlusion, Macular Degeneration Choroidal Neovascularization | Phase 4 | Completed | Retina Research Institute, LLC | 77 | 2021-08-20 | 2025-07-29 |
| Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration Brolucizumab - Age-related Macular Degeneration | Phase 4 | Completed | Novartis Pharmaceuticals | 52 | 2021-07-13 | 2025-09-26 |
| Visual Function Change in Wet Age-related Macular Degeneration Patients With Better Baseline Visual Acuity Aflibercept Injection [Eylea] - Age-Related Macular Degeneration | Phase 4 | Completed | Seoul National University Hospital | 12 | 2021-02-10 | 2024-03-26 |
| Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China OZURDEX - Macular Edema, Retinal Vein Occlusion | Phase 4 | Completed | Allergan | 150 | 2019-07-25 | 2023-03-31 |
| Povidone Iodine vs AVEnova: A Pre-injection Disinfection Study (PAVE Study) Povidone Iodine, Hypochlorous Acid - Age-related Macular Degeneration, Diabetic Retinopathy | Phase 4 | Completed | California Retina Consultants | 50 | 2019-07-16 | 2020-03-10 |
| FLIO and the Influence of Oral Lutein Supplementation on Macular Pigment NUTROF TOTAL - Age Related Macular Degeneration | Phase 4 | Completed | Insel Gruppe AG, University Hospital Bern | 28 | 2018-06-01 | 2023-01-26 |
| Study for Optimizing Anti-inflammatory Prophylaxis NSAID + prednisolone, preoperative, NSAID + prednisolone, postoperative, NSAID, preoperative - Postoperative Cystoid Macular Edema, Irvine-Gass Syndrome | Phase 4 | Completed | Line Kessel | 470 | 2018-02-01 | 2019-12-20 |
| An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy Treat and Extend with Aflibercept 2mg, Fixed Dosing with Aflibercept 2mg - Age Related Macular Degeneration, Polypoidal Choroidal Vasculopathy | Phase 4 | Completed | Singapore National Eye Centre | 54 | 2017-12-01 | 2021-08-18 |
Showing 20 of 103. Sign in to see all of them.
Macular Degeneration (52) · Macular Edema (44) · Choroidal Neovascularization (15) · Retinal Vein Occlusion (14) · Wet Macular Degeneration (12) · Diabetic Retinopathy (10) · Vision Disorders (9) · Cataract (6) · Geographic Atrophy (6) · Diabetes Mellitus (4) · Retinal Diseases (4) · Eye Diseases (3) · Polypoidal Choroidal Vasculopathy (3) · Eye Pain (2)
Eye Diseases (100) · Retinal Diseases (99) · Macular Degeneration (48) · Pathological Conditions, Signs and Symptoms (28) · Cardiovascular Diseases (23) · Vascular Diseases (23) · Pathologic Processes (22) · Uveal Diseases (21) · Metaplasia (20) · Neovascularization, Pathologic (19) · Choroid Diseases (18) · Embolism and Thrombosis (14) · Thrombosis (14) · Venous Thrombosis (14)
Ranibizumab (34) · aflibercept (21) · Bevacizumab (7) · Calcium Dobesilate (7) · Dexamethasone (6) · Verteporfin (5) · Ketorolac (4) · brolucizumab (4) · Triamcinolone (3) · bromfenac (3) · pegaptanib (3) · Cataract Extraction (2) · Moxifloxacin (2) · Ophthalmic Solutions (2) · Phacoemulsification (2)
Novartis Pharmaceuticals (17) · Allergan (3) · Bayer (3) · Medical University of Vienna (3) · Novartis (3) · Università degli Studi di Brescia (3) · California Retina Consultants (2) · Formycon AG (2) · Illinois Retina Associates (2) · Northern California Retina Vitreous Associates (2) · Rishi Singh (2) · Seoul National University Hospital (2) · The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery (2) · University of California, San Diego (2) · University of Campinas, Brazil (2)
United States (32) · Germany (9) · United Kingdom (8) · Austria (7) · South Korea (7) · Italy (6) · Japan (6) · Switzerland (6) · Canada (5) · France (5) · Spain (5) · Australia (4) · Brazil (4) · China (4) · India (4)
Christian Pruente, MD (2) · Rishi P Singh, MD (2) · Ursula Schmidt-Erfurth, MD (2) · Alana M Santana, MD (1) · Amod Gupta, MBBS MS (1) · Andrea Russo, MD (1) · Andreas Moan (1) · Barbara Wimpissinger, MD (1) · Brandon G Busbee, MD (1) · Carlos Buznego, MD (1)
PMID 11297486, PMID 12941734, PMID 12967792, PMID 17188044, PMID 17675159, PMID 18165083, PMID 1850220, PMID 18834580, PMID 1922252, PMID 19365036, PMID 19592101, PMID 20110127, PMID 20216291, PMID 21051706, PMID 21187730, PMID 22264944, PMID 22426346, PMID 22559899, PMID 22562296, PMID 22801846, PMID 22956609, PMID 23021093, PMID 23084240, PMID 23245386, PMID 23490325, PMID 23745581, PMID 24518078, PMID 24836866, PMID 25385061, PMID 25758601, PMID 26150052, PMID 26445522, PMID 27442130, PMID 28318636, PMID 28983556, PMID 29080915, PMID 30621653, PMID 30676617, PMID 30986442, PMID 31016030, PMID 31367468, PMID 31383649, PMID 31564356, PMID 31757691, PMID 32016788, PMID 32107066, PMID 32199867, PMID 32374423, PMID 32557168, PMID 32644148
2014 (4), 2009 (1), 2019 (1)